Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Arjo AB (FRA:A39) Q4 2024 Earnings Call Highlights: Strong North American Growth and Strategic ...

In This Article:

  • Organic Net Sales Growth: 3.1% for Q4 2024.

  • Gross Margin: 44.7% for Q4 2024.

  • Adjusted EBITDA: SEK653 million for Q4 2024, a 6.5% increase from the previous year.

  • Adjusted EBIT: Improved by almost 10% for Q4 2024.

  • Operating Cash Flow: SEK479 million for Q4 2024, with a cash conversion of 82%.

  • Full Year Organic Growth: 3.1% for 2024.

  • Full Year Gross Margin: Improved from 43.1% in 2023 to 43.5% in 2024.

  • Full Year Cash Conversion: 77% for 2024.

  • Net Debt: Decreased to SEK4.2 billion in Q4 2024.

  • Leverage: Improved to 2.0% net debt to adjusted EBITDA.

  • Equity Ratio: 51.2% in Q4 2024.

  • North America Organic Growth: Almost 8% for Q4 2024 and more than 5% for the full year.

  • Western Europe Organic Growth: Flat at 0.3% for Q4 2024 and 1.9% for the full year.

  • Rest of the World Organic Growth: Negative 3.7% for Q4 2024, but 4.1% for the full year.

Release Date: January 30, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Arjo AB (FRA:A39) reported a 3.1% organic net sales growth for Q4 2024, indicating a recovery from Q3.

  • The company saw strong growth in North America, with the US market showing positive development due to internal restructuring and improved customer financial situations.

  • Gross margin improved year-over-year from 43.1% to 43.5%, supported by lower material costs and price adjustments.

  • Adjusted EBITDA increased by 6.5% to SEK653 million, and adjusted EBIT improved by almost 10%, reflecting underlying profitability improvement.

  • The company launched a new product, the Symbliss bathing system, which has received positive customer feedback and is expected to strengthen market positions.

Negative Points

  • Challenges persist in Western European markets, particularly in France and the Netherlands, due to uncertainties in healthcare funding.

  • The rest of the world segment experienced a negative organic net sales growth of -3.7% in Q4, impacted by a tough comparison from the previous year.

  • Higher than normal salary inflation continues to be a headwind, affecting gross margin improvements.

  • Operating cash flow decreased to SEK479 million in Q4 2024 from SEK734 million in Q4 2023, due to working capital impacts.

  • The company faces ongoing challenges in China, with a weak finish to the year and a need to change market strategies for growth in 2025.

Q & A Highlights

Q: Could you share more details on the strong order growth mentioned in the presentation? Should we expect a strong first half of 2025, possibly towards the upper end of your 3% to 5% growth range? A: The order intake growth in Q4 was larger than the net sales growth, which is positive. We are entering 2025 with a larger order book, particularly in North America. However, the order book is delivered over time, so the impact will be seen throughout 2025 rather than immediately.